{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:11:19Z","timestamp":1761765079386},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,11,6]],"date-time":"2008-11-06T00:00:00Z","timestamp":1225929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s12032-008-9106-7","type":"journal-article","created":{"date-parts":[[2008,11,5]],"date-time":"2008-11-05T18:41:46Z","timestamp":1225910506000},"page":"186-192","source":"Crossref","is-referenced-by-count":25,"title":["Palliative chemotherapy for non-transitional cell carcinomas of the urothelial tract"],"prefix":"10.1007","volume":"26","author":[{"given":"Jung Yong","family":"Hong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moon Ki","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Jae","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeeyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joon Oh","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Won Ki","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun Moo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han Yong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hoyeong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,6]]},"reference":[{"key":"9106_CR1","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S0302-2838(03)00416-0","volume":"44","author":"P Dahm","year":"2003","unstructured":"Dahm P, Gschwend JE. Malignant non-urothelial neoplasms of the urinary bladder: a review. Eur Urol. 2003;44:672\u201381. doi: 10.1016\/S0302-2838(03)00416-0 .","journal-title":"Eur Urol"},{"key":"9106_CR2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1464-410X.2005.05327.x","volume":"95","author":"A Manunta","year":"2005","unstructured":"Manunta A, Vincendeau S, Kiriakou G, Lobel B, Guille F. Non-transitional cell bladder carcinomas. BJU Int. 2005;95:497\u2013502. doi: 10.1111\/j.1464-410X.2005.05327.x .","journal-title":"BJU Int"},{"key":"9106_CR3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.2004.02.152","volume":"22","author":"A Bamias","year":"2004","unstructured":"Bamias A, Aravantinos G, Deliveliotis C, Bafaloukos D, Kalofonos C, Xiros N, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220\u20138. doi: 10.1200\/JCO.2004.02.152 .","journal-title":"J Clin Oncol"},{"key":"9106_CR4","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cncr.21604","volume":"106","author":"A Bamias","year":"2006","unstructured":"Bamias A, Moulopoulos LA, Koutras A, Aravantinos G, Fountzilas G, Pectasides D, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 2006;106:297\u2013303. doi: 10.1002\/cncr.21604 .","journal-title":"Cancer"},{"issue":"Suppl 5","key":"9106_CR5","doi-asserted-by":"crossref","first-page":"v118","DOI":"10.1093\/annonc\/mdj965","volume":"17","author":"JT Roberts","year":"2006","unstructured":"Roberts JT, von der Maase H, Sengelov L, Conte PF, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine\/cisplatin and methotrexate\/vinblastine\/doxorubicin\/cisplatin in patients with locally advanced and metastatic bladder cancer. Ann Oncol. 2006;17(Suppl 5):v118\u201322. doi: 10.1093\/annonc\/mdj965 .","journal-title":"Ann Oncol"},{"key":"9106_CR6","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Maase von der","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602\u20138. doi: 10.1200\/JCO.2005.07.757 .","journal-title":"J Clin Oncol"},{"key":"9106_CR7","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/cncr.20123","volume":"100","author":"R Dreicer","year":"2004","unstructured":"Dreicer R, Manola J, Roth BJ, See WA, Kuross S, Edelman MJ, et al. Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer. 2004;100:1639\u201345. doi: 10.1002\/cncr.20123 .","journal-title":"Cancer"},{"key":"9106_CR8","doi-asserted-by":"crossref","unstructured":"Serretta V, Pomara G, Piazza F, Gange E. Pure squamous cell carcinoma of the bladder in western countries. Report on 19 consecutive cases. Eur Urol. 2000;37:85\u20139. doi: 10.1159\/000020105 .","DOI":"10.1159\/000020105"},{"key":"9106_CR9","first-page":"3865","volume":"26","author":"E Kastritis","year":"2006","unstructured":"Kastritis E, Dimopoulos MA, Antoniou N, Deliveliotis C, Chrisofos M, Skolarikos A, et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res. 2006;26:3865\u20139.","journal-title":"Anticancer Res"},{"key":"9106_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.urology.2006.10.029","volume":"69","author":"MD Galsky","year":"2007","unstructured":"Galsky MD, Iasonos A, Mironov S, Scattergood J, Donat SM, Bochner BH, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007;69:255\u20139. doi: 10.1016\/j.urology.2006.10.029 .","journal-title":"Urology"},{"key":"9106_CR11","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/cncr.20903","volume":"103","author":"NW Choong","year":"2005","unstructured":"Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005;103:1172\u20138. doi: 10.1002\/cncr.20903 .","journal-title":"Cancer"},{"key":"9106_CR12","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1464-410X.2004.04588.x","volume":"93","author":"AA Shokeir","year":"2004","unstructured":"Shokeir AA. Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU Int. 2004;93:216\u201320. doi: 10.1111\/j.1464-410X.2004.04588.x .","journal-title":"BJU Int"},{"key":"9106_CR13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer Sr","year":"1992","unstructured":"Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992;10:1066\u201373.","journal-title":"J Clin Oncol"},{"key":"9106_CR14","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","volume":"18","author":"H Maase von der","year":"2000","unstructured":"von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068\u201377.","journal-title":"J Clin Oncol"},{"key":"9106_CR15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.1990.8.6.1050","volume":"8","author":"CJ Logothetis","year":"1990","unstructured":"Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050\u20135.","journal-title":"J Clin Oncol"},{"key":"9106_CR16","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1200\/JCO.2000.18.9.1921","volume":"18","author":"D Kaufman","year":"2000","unstructured":"Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18:1921\u20137.","journal-title":"J Clin Oncol"},{"key":"9106_CR17","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.1999.17.9.2876","volume":"17","author":"MJ Moore","year":"1999","unstructured":"Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:2876\u201381.","journal-title":"J Clin Oncol"},{"key":"9106_CR18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1159\/000089993","volume":"69","author":"V Adamo","year":"2005","unstructured":"Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, et al. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology. 2005;69:391\u20138. doi: 10.1159\/000089993 .","journal-title":"Oncology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9106-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-008-9106-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-008-9106-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T02:22:35Z","timestamp":1559442155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-008-9106-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,6]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9106"],"URL":"https:\/\/doi.org\/10.1007\/s12032-008-9106-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,6]]}}}